CLDI
Calidi Biotherapeutics, Inc.
Price Chart
Latest Quote
$0.17
+0.02 (+11.12%)
Current Price
| Previous Close | $0.15 |
| Open | $0.15 |
| Day High | $0.17 |
| Day Low | $0.15 |
| Volume | 9,212,702 |
Stock Information
| Shares Outstanding | 19.31M |
| Total Debt | $2.26M |
| Cash Equivalents | $6.63M |
| Net Income | $-24.39M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $3.26M |
| EPS (TTM) | $-4.17 |
| Exchange | ASE |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-1.30M |
| Income | $-24.39M |
| Book/sh | $0.51 |
| Cash/sh | $0.34 |
| Employees | 29 |
Financial Ratios
| Quick Ratio | 1.73 |
| Current Ratio | 1.92 |
| Debt/Eq | 45.73 |
Returns & Margins
| ROA | -98.18% |
| ROE | -312.39% |
Ownership
| Insider Ownership | 1.87% |
| Institutional Ownership | 10.40% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.19 |
| P/B | 0.33 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.17 |
| SMA50 | $0.20 |
| SMA200 | $0.92 |
| RSI | 41.49 |
| ATR | 0.0170 |
| Shares Float | 18.73M |
| Short Float | 3.92% |
| Short Ratio | 0.28 |
| Rel Volume | 2.38 |
Performance History
| Week | +0.00% |
| Month | -8.15% |
| Quarter | -43.67% |
| 6 Months | -87.00% |
| YTD | -85.68% |
| Year | -95.46% |
| 3 Years | -99.99% |
| 10 Years | -99.99% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $0.17 | 10,857,100 |
| 2026-06-17 | $0.15 | 4,095,600 |
| 2026-06-16 | $0.16 | 6,448,300 |
| 2026-06-15 | $0.16 | 2,761,800 |
| 2026-06-12 | $0.15 | 10,928,500 |
| 2026-06-11 | $0.17 | 5,453,700 |
| 2026-06-10 | $0.17 | 2,389,700 |
| 2026-06-09 | $0.17 | 3,517,200 |
| 2026-06-08 | $0.17 | 3,577,000 |
| 2026-06-05 | $0.17 | 1,503,500 |
| 2026-06-04 | $0.17 | 3,193,900 |
| 2026-06-03 | $0.17 | 13,052,500 |
| 2026-06-02 | $0.18 | 4,429,700 |
| 2026-06-01 | $0.18 | 2,849,200 |
| 2026-05-29 | $0.19 | 1,605,300 |
| 2026-05-28 | $0.19 | 2,283,000 |
| 2026-05-27 | $0.19 | 4,259,300 |
| 2026-05-26 | $0.18 | 4,928,400 |
| 2026-05-22 | $0.18 | 1,595,400 |
| 2026-05-21 | $0.19 | 1,677,300 |
| 2026-05-20 | $0.17 | 1,809,100 |
| 2026-05-19 | $0.18 | 1,611,900 |
About Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as NeuroNova and SuperNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $45,000 |
| Operating Revenue | $0 | $0 | $0 | $45,000 |
| Reconciled Cost Of Revenue | - | - | $0 | $14,000 |
| Cost Of Revenue | - | - | $0 | $14,000 |
| Expenses | ||||
| Interest Expense | $207,000 | $933,000 | $1,069,000 | $158,000 |
| Total Expenses | $20,190,000 | $21,595,000 | $26,107,000 | $23,173,000 |
| Other Income Expense | $349,000 | $333,000 | $656,000 | $-2,130,000 |
| Other Non Operating Income Expenses | $103,000 | $9,000 | $-51,000 | $-5,000 |
| Net Non Operating Interest Income Expense | $-207,000 | $-933,000 | $-3,749,000 | $-158,000 |
| Interest Expense Non Operating | $207,000 | $933,000 | $1,069,000 | $158,000 |
| Operating Expense | $20,190,000 | $21,595,000 | $26,107,000 | $23,159,000 |
| Other Operating Expenses | $-50,000 | $-181,000 | $-2,885,000 | - |
| General And Administrative Expense | $10,503,000 | $12,898,000 | $15,984,000 | $15,902,000 |
| Total Other Finance Cost | - | - | $2,680,000 | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-19,906,000 | $-22,143,000 | $-29,216,000 | $-25,427,000 |
| Net Interest Income | $-207,000 | $-933,000 | $-3,749,000 | $-158,000 |
| Normalized Income | $-20,152,000 | $-22,398,960 | $-29,774,530 | $-23,748,250 |
| Net Income From Continuing And Discontinued Operation | $-19,906,000 | $-22,143,000 | $-29,216,000 | $-25,427,000 |
| Total Operating Income As Reported | $-20,240,000 | $-21,776,000 | $-28,992,000 | $-23,128,000 |
| Net Income Common Stockholders | $-25,579,000 | $-23,814,000 | $-29,216,000 | $-25,427,000 |
| Net Income | $-19,906,000 | $-22,143,000 | $-29,216,000 | $-25,427,000 |
| Net Income Including Noncontrolling Interests | $-20,063,000 | $-22,209,000 | $-29,216,000 | $-25,427,000 |
| Net Income Continuous Operations | $-20,063,000 | $-22,209,000 | $-29,216,000 | $-25,427,000 |
| Pretax Income | $-20,048,000 | $-22,195,000 | $-29,200,000 | $-25,416,000 |
| Special Income Charges | $244,000 | $0 | $-471,000 | $0 |
| Operating Income | $-20,190,000 | $-21,595,000 | $-26,107,000 | $-23,128,000 |
| Gross Profit | - | - | $0 | $31,000 |
| Per Share | ||||
| Diluted EPS | $-5.95 | $-35.70 | $-207.96 | $-84.98 |
| Basic EPS | $-5.95 | $-35.70 | $-207.96 | $-84.98 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $68,040 | $148,470 | $-446,250 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-18,436,000 | $-20,051,000 | $-27,582,000 | $-22,880,000 |
| Total Unusual Items | $246,000 | $324,000 | $707,000 | $-2,125,000 |
| Total Unusual Items Excluding Goodwill | $246,000 | $324,000 | $707,000 | $-2,125,000 |
| Reconciled Depreciation | $1,651,000 | $1,535,000 | $1,256,000 | $253,000 |
| EBITDA (Bullshit earnings) | $-18,190,000 | $-19,727,000 | $-26,875,000 | $-25,005,000 |
| EBIT | $-19,841,000 | $-21,262,000 | $-28,131,000 | $-25,258,000 |
| Diluted Average Shares | $4,302,000 | $667,000 | $140,499 | $299,221 |
| Basic Average Shares | $4,302,000 | $667,000 | $140,499 | $299,221 |
| Diluted NI Availto Com Stockholders | $-25,579,000 | $-23,814,000 | $-29,216,000 | $-25,427,000 |
| Otherunder Preferred Stock Dividend | $5,673,000 | $1,671,000 | $0 | - |
| Minority Interests | $157,000 | $66,000 | $0 | - |
| Tax Provision | $15,000 | $14,000 | $16,000 | $11,000 |
| Gain On Sale Of Business | $244,000 | $0 | - | - |
| Gain On Sale Of Security | $2,000 | $324,000 | $1,178,000 | $-2,125,000 |
| Research And Development | $9,737,000 | $8,878,000 | $13,008,000 | $7,257,000 |
| Selling General And Administration | $10,503,000 | $12,898,000 | $15,984,000 | $15,902,000 |
| Other Gand A | $10,503,000 | $12,898,000 | $15,984,000 | $15,902,000 |
| Other Special Charges | - | - | $471,000 | - |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $3,759,000 | $1,534,000 | $-8,235,000 | $-50,440,000 |
| Total Assets | $8,857,000 | $14,182,000 | $10,019,000 | $2,597,000 |
| Total Non Current Assets | $2,601,000 | $3,955,000 | $5,716,000 | $1,811,000 |
| Other Non Current Assets | $138,000 | $152,000 | $373,000 | $725,000 |
| Current Assets | $6,256,000 | $10,227,000 | $4,303,000 | $786,000 |
| Other Current Assets | $234,000 | $249,000 | $225,000 | $303,000 |
| Prepaid Assets | $422,000 | $387,000 | $769,000 | $111,000 |
| Cash Cash Equivalents And Short Term Investments | $5,600,000 | $9,591,000 | $1,949,000 | $372,000 |
| Cash And Cash Equivalents | $5,600,000 | $9,591,000 | $1,949,000 | $372,000 |
| Cash Financial | $5,600,000 | $9,591,000 | $1,949,000 | $372,000 |
| Receivables | - | $0 | $1,360,000 | $0 |
| Financial Assets | - | - | $230,000 | $0 |
| Other Receivables | - | - | $1,360,000 | - |
| Debt | ||||
| Total Debt | $2,564,000 | $7,036,000 | $7,236,000 | $5,988,000 |
| Long Term Debt And Capital Lease Obligation | $1,048,000 | $2,590,000 | $5,313,000 | $447,000 |
| Long Term Debt | $600,000 | $600,000 | $2,060,000 | - |
| Current Debt And Capital Lease Obligation | $1,516,000 | $4,446,000 | $1,923,000 | $5,541,000 |
| Current Debt | - | $3,176,000 | $807,000 | $5,425,000 |
| Other Current Borrowings | - | $3,176,000 | $807,000 | $5,425,000 |
| Net Debt | - | - | $918,000 | $5,053,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $5,098,000 | $12,214,000 | $18,254,000 | $53,037,000 |
| Total Non Current Liabilities Net Minority Interest | $1,163,000 | $2,718,000 | $8,022,000 | $10,048,000 |
| Derivative Product Liabilities | $115,000 | $128,000 | $671,000 | $0 |
| Current Liabilities | $3,935,000 | $9,496,000 | $10,232,000 | $42,989,000 |
| Payables And Accrued Expenses | $2,419,000 | $5,050,000 | $8,309,000 | $7,618,000 |
| Payables | $613,000 | $2,712,000 | $2,877,000 | $2,271,000 |
| Accounts Payable | $595,000 | $2,072,000 | $2,796,000 | $2,124,000 |
| Tradeand Other Payables Non Current | - | $0 | $0 | - |
| Other Non Current Liabilities | - | - | $1,500,000 | - |
| Current Notes Payable | - | - | $529,000 | $507,000 |
| Other Current Liabilities | - | - | - | $29,830,000 |
| Equity | ||||
| Common Stock Equity | $3,759,000 | $1,534,000 | $-8,235,000 | $-50,440,000 |
| Total Equity Gross Minority Interest | $3,759,000 | $1,968,000 | $-8,235,000 | $-50,440,000 |
| Stockholders Equity | $3,759,000 | $1,534,000 | $-8,235,000 | $-50,440,000 |
| Gains Losses Not Affecting Retained Earnings | $-13,000 | $-28,000 | $-47,000 | $-14,000 |
| Other Equity Adjustments | $-13,000 | $-28,000 | $-47,000 | $-14,000 |
| Retained Earnings | $-141,621,000 | $-121,715,000 | $-99,572,000 | $-70,356,000 |
| Preferred Securities Outside Stock Equity | - | - | $0 | $9,601,000 |
| Other | ||||
| Ordinary Shares Number | $7,216,994 | $1,730,017 | $296,018 | $299,221 |
| Share Issued | $7,216,994 | $1,730,017 | $296,018 | $299,221 |
| Tangible Book Value | $3,759,000 | $1,534,000 | $-8,235,000 | $-50,440,000 |
| Invested Capital | $4,359,000 | $5,310,000 | $-5,368,000 | $-45,015,000 |
| Working Capital | $2,321,000 | $731,000 | $-5,929,000 | $-42,203,000 |
| Capital Lease Obligations | $1,964,000 | $3,260,000 | $4,369,000 | $563,000 |
| Total Capitalization | $4,359,000 | $2,134,000 | $-6,175,000 | $-50,440,000 |
| Minority Interest | $0 | $434,000 | $0 | - |
| Additional Paid In Capital | $145,392,000 | $123,277,000 | $91,383,000 | $19,928,000 |
| Capital Stock | $1,000 | $0 | $1,000 | $2,000 |
| Common Stock | $1,000 | $0 | $1,000 | $2,000 |
| Long Term Capital Lease Obligation | $448,000 | $1,990,000 | $3,253,000 | $447,000 |
| Current Capital Lease Obligation | $1,516,000 | $1,270,000 | $1,116,000 | $116,000 |
| Current Accrued Expenses | $1,806,000 | $2,338,000 | $5,432,000 | $5,347,000 |
| Dueto Related Parties Current | $18,000 | $640,000 | $81,000 | $147,000 |
| Net PPE | $2,463,000 | $3,803,000 | $5,343,000 | $1,086,000 |
| Accumulated Depreciation | $-1,794,000 | $-1,355,000 | $-993,000 | $-631,000 |
| Gross PPE | $4,257,000 | $5,158,000 | $6,336,000 | $1,717,000 |
| Other Properties | $1,682,000 | $2,934,000 | $4,073,000 | $199,000 |
| Machinery Furniture Equipment | $2,575,000 | $2,224,000 | $2,263,000 | $1,518,000 |
| Dueto Related Parties Non Current | - | $0 | $538,000 | - |
| Treasury Shares Number | - | - | $0 | - |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-21,413,000 | $-19,710,000 | $-27,568,000 | $-13,642,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-21,293,000 | $-19,694,000 | $-26,983,000 | $-13,214,000 |
| Cash Flow From Continuing Operating Activities | $-21,293,000 | $-19,694,000 | $-26,983,000 | $-13,214,000 |
| Operating Gains Losses | $-244,000 | - | $476,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-120,000 | $-16,000 | $-585,000 | $-428,000 |
| Investing Cash Flow | $-170,000 | $-16,000 | $-478,000 | $-494,000 |
| Cash Flow From Continuing Investing Activities | $-170,000 | $-16,000 | $-478,000 | $-494,000 |
| Net Other Investing Changes | - | - | $98,000 | $-66,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $16,654,000 | $18,065,000 | $27,260,000 | $0 |
| Financing Cash Flow | $17,459,000 | $27,365,000 | $29,044,000 | $12,087,000 |
| Cash Flow From Continuing Financing Activities | $17,459,000 | $27,365,000 | $29,044,000 | $12,087,000 |
| Net Other Financing Charges | $-846,000 | $437,000 | $604,000 | $10,592,000 |
| Net Common Stock Issuance | $16,654,000 | $18,065,000 | $2,763,000 | $0 |
| Common Stock Issuance | $16,654,000 | $18,065,000 | $2,763,000 | $0 |
| Net Preferred Stock Issuance | - | $0 | $24,497,000 | $0 |
| Preferred Stock Issuance | - | $0 | $24,497,000 | $0 |
| Repurchase Of Capital Stock | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $-2,490,000 | $-1,882,000 | $-2,351,000 | $-119,000 |
| Issuance Of Debt | $0 | $3,800,000 | $3,250,000 | $1,500,000 |
| Interest Paid Supplemental Data | $1,265,000 | $140,000 | $404,000 | $35,000 |
| Income Tax Paid Supplemental Data | $17,000 | $14,000 | $11,000 | $11,000 |
| End Cash Position | $5,819,000 | $9,809,000 | $2,167,000 | $590,000 |
| Beginning Cash Position | $9,809,000 | $2,167,000 | $590,000 | $2,237,000 |
| Effect Of Exchange Rate Changes | $14,000 | $-13,000 | $-6,000 | $-26,000 |
| Changes In Cash | $-4,004,000 | $7,655,000 | $1,583,000 | $-1,621,000 |
| Proceeds From Stock Option Exercised | $4,141,000 | $6,945,000 | $281,000 | $114,000 |
| Net Issuance Payments Of Debt | $-2,490,000 | $1,918,000 | $899,000 | $1,381,000 |
| Net Short Term Debt Issuance | $-200,000 | $200,000 | $3,250,000 | $1,500,000 |
| Short Term Debt Payments | $-200,000 | $0 | $-300,000 | $0 |
| Short Term Debt Issuance | $0 | $200,000 | $3,250,000 | $1,500,000 |
| Net Long Term Debt Issuance | $-2,290,000 | $1,718,000 | $-2,351,000 | $-119,000 |
| Long Term Debt Payments | $-2,290,000 | $-1,882,000 | $-2,351,000 | $-119,000 |
| Long Term Debt Issuance | $0 | $3,600,000 | $0 | - |
| Net Business Purchase And Sale | $-50,000 | $0 | $9,000 | $0 |
| Purchase Of Business | $-50,000 | $0 | - | - |
| Net PPE Purchase And Sale | $-120,000 | $-16,000 | $-585,000 | $-428,000 |
| Purchase Of PPE | $-120,000 | $-16,000 | $-585,000 | $-428,000 |
| Change In Working Capital | $-4,743,000 | $-1,698,000 | $-6,242,000 | $3,569,000 |
| Change In Other Current Liabilities | $-1,380,000 | $-1,017,000 | $872,000 | $0 |
| Change In Payables And Accrued Expense | $-3,321,000 | $-2,482,000 | $-4,895,000 | $3,399,000 |
| Change In Accrued Expense | $-1,993,000 | $-1,854,000 | $1,275,000 | $1,775,000 |
| Change In Payable | $-1,328,000 | $-628,000 | $-6,170,000 | $1,624,000 |
| Change In Account Payable | $-1,328,000 | $-628,000 | $-6,170,000 | $1,624,000 |
| Change In Prepaid Assets | $-42,000 | $1,801,000 | $-2,219,000 | $170,000 |
| Other Non Cash Items | $-2,000 | $-279,000 | $1,934,000 | $2,248,000 |
| Stock Based Compensation | $2,108,000 | $2,957,000 | $4,809,000 | $6,143,000 |
| Depreciation Amortization Depletion | $1,651,000 | $1,535,000 | $1,256,000 | $253,000 |
| Depreciation And Amortization | $1,651,000 | $1,535,000 | $1,256,000 | $253,000 |
| Gain Loss On Sale Of Business | $-244,000 | $0 | - | - |
| Net Income From Continuing Operations | $-20,063,000 | $-22,209,000 | $-29,216,000 | $-25,427,000 |
| Sale Of Business | - | $0 | $9,000 | $0 |
| Depreciation | - | $1,535,000 | $1,256,000 | $253,000 |
| Gain Loss On Sale Of PPE | - | $0 | $5,000 | $0 |
| Preferred Stock Payments | - | - | - | - |
| Unrealized Gain Loss On Investment Securities | - | - | - | - |
Fetched: 2026-06-17